ViscoTec hosts Additive Manufacturing Experience Day at Töging am Inn Innovation Center

ViscoTec, a German fluid technology specialist, hosted its Additive Manufacturing Experience Day at its Customer and Innovation Center (CIC) in Töging am Inn, focusing on liquid and paste 3D printing. The full-day event covered the company's entire process chain—from material feeding and dosing to finished parts—with its progressive cavity pump technology at the core. Presentations and live demonstrations highlighted medical device applications and bioprinting, including 3D-printed silicone organ models for surgical planning and training, as well as RTV silicone and liquid silicone rubber (LSR) for prototyping, spare parts, and custom medical solutions. ViscoTec showcased its Medical-Grade product line using FDA-compliant polymers and the Puredyne Kit b dosing system, designed for gentle handling of living cells in bioprinting. Participants included Jannik Stadler, Head of Bioprinting Consumables and Services at BlackDrop; Benedikt Daschner, Quality Manager and AM developer at CR-3D; and Chad Copperthite from Rosenheim University of Applied Sciences, a cooperation partner.

This event underscores a recurring industry pattern: the gradual pull-through of AM into medical and bioprinting verticals, where material handling precision—not just print speed or build volume—is the critical differentiator. ViscoTec's focus on progressive cavity pumps for high-viscosity, shear-sensitive materials (silicones, polyurethanes, conductive pastes, ceramics, biological substances) positions it at the intersection of polymer-vpp and bioprinting process segments, competing indirectly with systems from Cellink, regenHU, and EnvisionTEC in the medical modeling and tissue engineering space. The emphasis on FDA-compliant polymers and surgical models aligns with the medical-dental vertical's growing demand for patient-specific anatomical replicas, a market that remains fragmented but is accelerating as hospitals seek to reduce surgical risk and training costs. The event's academic partnership with Rosenheim University also reflects the research-academic vertical's role in validating new material-process combinations before they reach clinical or industrial scale.

For ViscoTec, the practical takeaway is that its dosing expertise—honed in industrial fluid handling—now has a credible path into regulated medical applications, but the company must demonstrate repeatable quality across multiple material lots and user sites to move beyond prototyping. The presence of BlackDrop, a bioprinting system maker, suggests potential upstream integration opportunities, while CR-3D's interest in serial production scaling signals that the technology is being evaluated for more than one-off models. The next step for ViscoTec is to convert these demonstration-day leads into qualified customer pilots with documented process validation.